The Constraint
Conventional drugs miss ~80% of the disease-relevant proteins
Small molecules, biologics, and most emerging modalities depend on pre-existing, detectable binding sites — accessing fewer than 15% of the proteome and leaving most disease-driving proteins out of reach.
The Gap
Induced proximity has been serendipitous
Recent advances have begun to unlock these targets, but discovery has been largely accidental. No systematic framework exists — success cannot be predicted or reproduced at scale.
The Opportunity
A systematic framework doesn't exist yet
Protein surfaces encode a vast, unmapped interaction landscape. The biology to program novel functional interactions exists — what's missing is the platform to access it systematically.
Why Now
Four fields have matured — and only now are powerful enough to combine
Together they make it possible to systematically engage a class of targets that has resisted every prior generation of therapeutics.
AI/ML for Biology
AlphaFold and successors made protein structure computationally tractable — turning surfaces into data.
Structural Biology
Atomic-resolution understanding of interfaces and dynamic conformations invisible to earlier methods.
Next-Generation Modalities
Therapeutics engineered for surface and interface biology — reaching targets small molecules cannot.
Induced Proximity
FDA-validated molecular glues proved that induced proximity produces real therapeutic outcomes.
Our Platform
ARC-Engine:
A single platform. Multiple Application
Analyze
Builds a comprehensive view of the protein interaction landscape to reveal opportunities invisible to conventional approaches.
Resolve
Identifies compatible protein pairings with the highest potential for programmable biological control.
Construct
Translates platform insights into therapeutic candidates designed for precision and purpose.
Closed-loop learning:
The platform learns from every experiment, improving discovery speed and candidate quality over time.
